UNSPSC 51433104: Spirapril hydrochloride

This classification denotes an ace inhibitor with the molecular formula C22H30N2O5S2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OCC25LM897, chemically known as 1,4-dithia-7-azaspiro(4.4)nonane-8-carboxylic acid, 7-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-, monohydrochloride, (8s-(7(r*(r*)),8r*))- but more generally known as spirapril hydrochloride, which bears US NIH Compound Identifier 71192.

UNSPSC 51433104 Spirapril hydrochloride is a Commodity code covering pharmaceutical compounds for distribution through state and local healthcare systems. State and local governments procure under this code primarily through emergency medical services agencies, health departments, and multi-state cooperative purchasing alliances that aggregate demand across institutional buyers. The scope of work includes supplying manufacturers' pharmaceutical products—both branded and generic formulations—through authorized wholesale distributors to support emergency response, public health programs, and institutional pharmacy networks. Recent solicitations show that jurisdictions are acquiring specific pharmaceuticals in unit quantities ranging from hundreds to thousands of doses, with firm pricing inclusive of freight, storage and expiration management, compliance with FDA requirements and Good Manufacturing Practices, and delivery within days to weeks of order placement. Purchasing entities require vendors to maintain liability and product liability insurance, provide Safety Data Sheets and accessibility documentation, comply with drug supply chain security regulations, and warrant products against defects for extended periods.

Activity under the code spans multiple issuing-body types, with the most recent opportunities originating from a city fire-rescue agency (City of Tampa), a state health commission (Texas HHS), and a multi-state cooperative purchasing alliance (Minnesota Multistate Cooperative Purchasing Alliance serving Minnesota and Oregon). The City of Tampa issued an IFB for Advanced Life Support Medications with a due date of April 8, 2026, and an estimated contract value of $40,000 with a Small Local Business Enterprise set-aside and five percent bid discount; Texas HHS issued an RFI on direct-to-manufacturer pharmacy programs with no specific award value or set-asides disclosed; and MMCAP issued an RFP for generic multi-source pharmaceuticals due March 26, 2026, with a two-year term and performance penalties ranging from $200 to $1,500 per violation. Geographic activity centers on Florida, Texas, and the Upper Midwest (Minnesota and Oregon), with cooperative purchasing vehicles extending reach across multiple state and local jurisdictions simultaneously.